Connect Biopharma Presents Data Supporting Rademikibart at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress

Core Insights - Rademikibart has shown significant improvements in lung function and asthma control for patients with eosinophilic-driven type 2 asthma [1][2] - The treatment has led to a reduction in annualized exacerbation rates in the same patient group [1][10] - Ongoing Phase 2 studies for acute exacerbations in asthma and COPD are expected to report topline data in the first half of 2026 [1] Company Overview - Connect Biopharma is a clinical-stage biopharmaceutical company focused on asthma and COPD treatment [6] - The company is advancing rademikibart, a next-generation anti-interleukin-4-receptor alpha (IL-4Rα) antibody [6] - Rademikibart targets acute exacerbations, addressing a significant unmet need among asthma and COPD patients [6] Clinical Data Highlights - In a Phase 2b trial, rademikibart improved prebronchodilator forced expiratory volume in one second (FEV1) within one week, sustained through 24 weeks [3] - The treatment showed greater improvement in patients with elevated baseline eosinophil counts compared to the overall population [3] - Rademikibart demonstrated a 63% reduction in annualized asthma exacerbation rates (AAER) in patients with elevated eosinophils, 69% in those with elevated FeNO, and 74% in patients with both markers [10]